Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Gross Profit: 2018-2024

Historic Gross Profit for Allogene Therapeutics (ALLO) over the last 5 years, with Dec 2024 value amounting to $22,000.

  • Allogene Therapeutics' Gross Profit fell 244.00% to -$344,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$843,000, marking a year-over-year decrease of 2308.57%. This contributed to the annual value of $22,000 for FY2024, which is 76.84% down from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' Gross Profit is $22,000, which was down 76.84% from $95,000 recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Gross Profit peaked at $114.1 million during FY2021, and registered a low of $22,000 during FY2024.
  • Over the past 3 years, Allogene Therapeutics' median Gross Profit value was $95,000 (recorded in 2023), while the average stood at $91,000.
  • Data for Allogene Therapeutics' Gross Profit shows a maximum YoY plummeted of 99.86% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Allogene Therapeutics' Gross Profit stood at $114.1 million in 2021, then crashed by 99.86% to $156,000 in 2022, then crashed by 39.10% to $95,000 in 2023, then tumbled by 76.84% to $22,000 in 2024.